Dr.Gayatri Dasari

Abstract

Study design: Descriptive case series
Purpose: To assess the efficacy of 0.01% Atropine eye drops in delaying or halting myopia progression in children <16 years.
Methods: Children (5-16 years) with progressing myopia (≥0.5D increase in the past year) and spherical equivalent ≤-1.00D in each eye were enrolled after obtaining informed assent. Ocular examination measured parameters, including spherical equivalent, axial length, keratometry, anterior chamber depth, lens thickness, and pupil size. Children received topical atropine 0.01% eye drops once daily at night for both eyes for two years. Safety was evaluated through questionnaires.
Results: Eight children (ages 9-16, 5 females, three males) enrolled. After two years, there was no increase in spherical equivalent, and no adverse symptoms related to atropine use, resulting in a 100% success rate.
Conclusion: Low-dose atropine 0.01% eye drops effectively halted myopia progression in children (5-16 years) and demonstrated tolerability.